SciSparc Ltd
Company Profile
Business description
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company’s operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Contact
20 Raul Wallenberg Street
Tower A, 2nd Floor
Tel Aviv6971916
ISRT: +972 37175777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
Our top ASX picks in every sector
stocks
Potentially catastrophic ruling for ASX company
stocks
4 charts on Nvidia’s record $4 trillion market cap
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,875.30 | 60.00 | 0.68% |
CAC 40 | 7,766.21 | 41.96 | -0.54% |
DAX 40 | 24,060.29 | 100.35 | -0.42% |
Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
FTSE 100 | 8,938.32 | 59.74 | -0.66% |
HKSE | 24,590.12 | 386.80 | 1.60% |
NASDAQ | 20,677.80 | 37.47 | 0.18% |
Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
S&P 500 | 6,243.76 | 24.80 | -0.40% |
S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
SSE Composite Index | 3,505.00 | 14.65 | -0.42% |